In muscle-invasive bladder cancer, ctDNA-guided adjuvant atezolizumab improved disease-free and overall survival. Proud to be part of this work, with @tompowles1 and all colleagues, patients, families, and sponsors who made it real. @NEJM @myESMO #ESMO25 @OncoBellmunt

1/4 IMVIGOR011 shows ctDNA is a useful predictive and prognostic tool post cystectomy in muscle invasive bladder cancer #ESMO25 . ctDNA positive patients had DFS and OS benifits with atezolizumab. ctDNA negative patients are at a low risk of relapse/cancer death. @OncoAlert

Optimized use of targeted therapies in mCRPC, by @AOmlin #ESMO25

🤔???

🚨ENZARAD at #ESMO25 presented by @DrPaulNguyen No improvement in MFS or OS with the addition of enzalutamide to high dose radiotherapy + 2y ADT in high risk #prostatecancer Possible benefit in cN1 pts or pts treated with pelvic RT.

Confirmado: ENZA combo aumenta la supervivencia en la recidiva bioquímica de alto riesgo (CPHSnm). Estudio EMBARK #ESMO25

Breaking news from #ESMO25👉Improved OS in high risk biochemical recurrent #ProstateCancer on with ENZA+ADT vs ADT alone, HR: 0.59 (no OS benefit with ENZA monotherapy), 👏wonderful news for our pts👉congrats @SFreedlandMD @nealshore & the team. @OncoAlert @urotoday @PCF_Science

Elegant discussion by @Tilki_De reconciling EMBARK & PRESTO #ESMO25: 1. Differences in trial size and 1ry endpoint 2. inclusion criteria close, but pts in EMBARK much higher risk 3. PSMA allowed in PRESTO Important to assess individual risk to select pt for intensification

2420MO – STOPCAP Meta-analysis #ESMO25 📊 Pooled IPD from PEACE-1 & STAMPEDE: prostate RT in synchronous mHSPC. ⚖️ No overall OS benefit (HR 0.93, p=0.11) ✅ Low-volume benefit: HR 0.79 → +7.7% 5-yr OS ✅ ≤4 bone mets: HR 0.84 (+4.9%) ➡️ Benefit confined to low-volume,

The most decisive step on the road to cure in muscle-invasive bladder cancer was met with a standing ovation at #ESMO25 👏👏 A historic moment for uro-oncology. #BladderCancer #Oncology #Immunotherapy #ADC @myESMO @OncLive @CParkMD @tugbawitter @Dr_ElvinaA @atakansare2016

A new standard of care for cisplatin ineligible neoadjuvant/periop MIBC #ESMO25 3 separate ovations for EFS, OS, and pCR rate. Next horizon: bladder preservation. @OncoAlert @myESMO

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery

Key question is whether this would allow bladder preservation protocols and not cystectomy. What is the point of removing 57% of intact bladders? Could we do less to improve patients QoL? #radonc

Impresionante la marcha de @ContraCancerEs en #Salamanca

He oído que no queda ningún acelerador lineal funcionando en Cuba ¿es cierto que han tenido que recargar viejas Unidades de Cobalto? Adelante - Reactivan equipos de radioterapia en servicios oncológicos

HDR worse than LDR???

Salvage brachytherapy for locally recurrent prostate cancer after definitive radiotherapy – a multicentric French cohort by the SFRO brachytherapy group https://t.co/Cx1PxgvyMB This large retrospective cohort study—the largest to date on salvage prostate brachytherapy

🎯 From IFRT ➡️ ISRT ➡️ INRT How radiotherapy for lymphoma got smarter and smaller 🩻✨ In the old days, RT fields were like sledgehammers — now they’re scalpels. Here’s the evolution 🔽 🔹 IFRT – Involved-FIELD RT 🕰 Old school. Treats the whole lymph-node region — even if

Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines. https://t.co/GKKzPKkLHw

🧠 You can shrink the tumour—but not the tumour bed. New RAPIDO analysis in BJS 2025 shows why small margins after TNT can turn dangerous 👇 💡 Trial: RAPIDO (n = 920, LARC) 🎯 TNT = 5×5 Gy + 6 CAPOX / 9 FOLFOX → TME vs CRT = 25–28×1.8–2 Gy + capecitabine → TME 📊 8-year